Obesity and prostate cancer: Collateral damage in the battle of the bulge

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 2, 2011, Pages 594-605

  Thomas II, Jean Alfred ^a   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

BMI; Body mass index; Obesity; Prostate cancer; Review

Indexed keywords

ADIPONECTIN; C PEPTIDE; ESTROGEN; INSULIN; LEPTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; SEX HORMONE;

ARTICLE; BODY MASS; BODY WEIGHT; BRACHYTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; EXTERNAL BEAM RADIOTHERAPY; HEMODILUTION; HUMAN; INSULIN RELEASE; MALE; NEEDLE BIOPSY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; ROBOTICS; TESTOSTERONE BLOOD LEVEL; COMORBIDITY; DISEASE COURSE; METABOLISM; MORTALITY; PROSTATE TUMOR; REVIEW; RISK FACTOR;

COMORBIDITY; DISEASE PROGRESSION; GONADAL STEROID HORMONES; HUMANS; MALE; OBESITY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79955947776     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. K. M. Flegal, M. D. Carroll, C. L. Ogden and L. R. Curtin: Prevalence and trends in obesity among US adults, 1999-2008. Jama, 303(3), 235-41
2. A. Berghofer, T. Pischon, T. Reinhold, C. M. Apovian, A. M. Sharma and S. N. Willich: Obesity prevalence from a European perspective: A systematic review. BMC Public Health, 8, 200 (2008)
3. S. D. Malnick and H. Knobler: The medical complications of obesity. Qjm, 99(9), 565-79 (2006)
4. E. E. Calle, C. Rodriguez, K. Walker-Thurmond and M. J. Thun: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348(17), 1625-38 (2003)
5. E. E. Calle, L. R. Teras and M. J. Thun: Adiposity and physical activity as predictors of mortality. N Engl J Med, 352(13), 1381-4; author reply 1381-4 (2005)
6. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer
7. P. D. Baade, D. R. Youlden and L. J. Krnjacki: International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res, 53(2), 171-84 (2009)
8. F. H. Schroder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Maattanen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. Van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning and A. Auvinen: Screening and prostate-Cancer mortality in a randomized European study. N Engl J Med, 360(13), 1320-8 (2009)
9. J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, P. Lodding, C. G. Pihl, J. Stranne, E. Holmberg and H. Lilja: Mortality results from the Goteborg randomised population-Based prostate-Cancer screening trial. Lancet Oncol
10. M. Stacewicz-Sapuntzakis, G. Borthakur, J. L. Burns and P. E. Bowen: Correlations of dietary patterns with prostate health. Mol Nutr Food Res, 52(1), 114-30 (2008)
11. G. A. Sonn, W. Aronson and M. S. Litwin: Impact of diet on prostate cancer: A review. Prostate Cancer Prostatic Dis, 8(4), 304-10 (2005)
12. S. J. Freedland and W. J. Aronson: Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol, 19(3), 263-7 (2009)
13. Available at URL: Fttp: www.m-w.com/. Accessed July 25, 2010
14. Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 854, 1-452 (1995)
15. A. M. Prentice and S. A. Jebb: Beyond body mass index. Obes Rev, 2(3), 141-7 (2001)
16. P. Wallstrom, A. Bjartell, B. Gullberg, H. Olsson and E. Wirfalt: A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer, 100(11), 1799-805 (2009)
17. R. Huxley, S. Mendis, E. Zheleznyakov, S. Reddy and J. Chan: Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-A review of the literature. Eur J Clin Nutr, 64(1), 16-22
18. E. Giovannucci, E. B. Rimm, Y. Liu, M. Leitzmann, K. Wu, M. J. Stampfer and W. C. Willett: Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst, 95(16), 1240-4 (2003)
19. S. D. Putnam, J. R. Cerhan, A. S. Parker, G. D. Bianchi, R. B. Wallace, K. P. Cantor and C. F. Lynch: Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol, 10(6), 361-9 (2000)
20. S. O. Andersson, A. Wolk, R. Bergstrom, H. O. Adami, G. Engholm, A. Englund and O. Nyren: Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst, 89(5), 385-9 (1997)
21. M. B. Veierod, P. Laake and D. S. Thelle: Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men. Int J Cancer, 73(5), 634-8 (1997)
22. A. Engeland, S. Tretli and T. Bjorge: Feight, body mass index, and prostate cancer: A follow-up of 950000 Norwegian men. Br J Cancer, 89(7), 1237-42 (2003)
23. E. Giovannucci, Y. Liu, E. A. Platz, M. J. Stampfer and W. C. Willett: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer, 121(7), 1571-8 (2007)
24. A. G. Schuurman, R. A. Goldbohm, E. Dorant and P. A. Van Den Brandt: Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol, 151(6), 541-9 (2000)
25. T. I. Nilsen and L. J. Vatten: Anthropometry and prostate cancer risk: A prospective study of 22,248 Norwegian men. Cancer Causes Control, 10(4), 269-75 (1999)
26. R. J. MacInnis and D. R. English: Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control, 17(8), 989-1003 (2006)
27. M. P. Porter and J. L. Stanford: Obesity and the risk of prostate cancer. Prostate, 62(4), 316-21 (2005)
28. M. E. Wright, S. C. Chang, A. Schatzkin, D. Albanes, V. Kipnis, T. Mouw, P. Hurwitz, A. Hollenbeck and M. F. Leitzmann: Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer, 109(4), 675-84 (2007)
29. L. Dal Maso, A. Zucchetto, C. La Vecchia, M. Montella, E. Conti, V. Canzonieri, R. Talamini, A. Tavani, E. Negri, A. Garbeglio and S. Franceschi: Prostate cancer and body size at different ages: An Italian multicentre casecontrol study. Br J Cancer, 90(11), 2176-80 (2004)
30. E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz and W. C. Willett: Feight, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 6(8), 557-63 (1997)
31. W. R. Robinson, C. Poole and P. A. Godley: Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control, 19(8), 793-803 (2008)
32. Z. Gong, M. L. Neuhouser, P. J. Goodman, D. Albanes, C. Chi, A. W. Hsing, S. M. Lippman, E. A. Platz, M. N. Pollak, I. M. Thompson and A. R. Kristal: Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev, 15(10), 1977-83 (2006)
33. C. Rodriguez, S. J. Freedland, A. Deka, E. J. Jacobs, M. L. McCullough, A. V. Patel, M. J. Thun and E. E. Calle: Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev, 16(1), 63-9 (2007)
34. A. B. Rosen and E. C. Schneider: Colorectal cancer screening disparities related to obesity and gender. J Gen Intern Med, 19(4), 332-8 (2004)
35. C. D. Scales, Jr., L. H. Curtis, R. D. Norris, K. A. Schulman, P. Dahm and J. W. Moul: Relationship between body mass index and prostate cancer screening in the United States. J Urol, 177(2), 493-8 (2007)
36. W. S. Yancy, Jr., J. R. McDuffie, K. M. Stechuchak, M. K. Olsen, E. Z. Oddone, L. S. Kinsinger, S. K. Datta, D. A. Fisher, K. M. Krause and T. Ostbye: Obesity and Receipt of Clinical Preventive Services in Veterans. Obesity (Silver Spring)
37. J. Baillargeon, B. H. Pollock, A. R. Kristal, P. Bradshaw, J. Hernandez, J. Basler, B. Higgins, S. Lynch, T. Rozanski, D. Troyer and I. Thompson: The association of body mass index and prostate-specific antigen in a population-Based study. Cancer, 103(5), 1092-5 (2005)
38. J. H. Han, Y. T. Lee, K. W. Kwak, S. H. Ahn, I. H. Chang, S. C. Myung, S. Y. Oh, Y. S. Lee, W. Kim, Y. W. Jin, T. I. Choi and S. H. Sung: Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men. Asian J Androl, 12(3), 400-4
39. A. B. Barqawi, B. K. Golden, C. O'Donnell, M. K. Brawer and E. D. Crawford: Observed effect of age and body mass index on total and complexed PSA: Analysis from a national screening program. Urology, 65(4), 708-12 (2005)
40. M. A. Gray, B. Delahunt, J. R. Fowles, P. Weinstein, R. R. Cookes and J. N. Nacey: Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res, 24(3b), 2069-72 (2004)
41. J. L. Beebe-Dimmer, G. J. Faerber, H. Morgenstern, D. Werny, K. Wojno, B. Halstead-Nussloch and K. A. Cooney: Body composition and serum prostate-specific antigen: Review and findings from Flint Men's Health Study. Urology, 71(4), 554-60 (2008)
42. N. Parekh, Y. Lin, S. Marcella, A. K. Kant and G. Lu-Yao: Associations of lifestyle and physiologic factors with prostatespecific antigen concentrations: Evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev, 17(9), 2467-72 (2008)
43. L. L. Banez, R. J. Hamilton, A. W. Partin, R. T. Vollmer, L. Sun, C. Rodriguez, Y. Wang, M. K. Terris, W. J. Aronson, J. C. Presti, Jr., C. J. Kane, C. L. Amling, J. W. Moul and S. J. Freedland: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Jama, 298(19), 2275-80 (2007)
44. R. L. Grubb, 3rd, A. Black, G. Izmirlian, T. P. Hickey, P. F. Pinsky, J. E. Mabie, T. L. Riley, L. R. Ragard, P. C. Prorok, C. D. Berg, E. D. Crawford, T. R. Church and G. L. Andriole, Jr.: Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev, 18(3), 748-51 (2009)
45. J. H. Fowke and C. E. Matthews: PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate, 70(2), 120-5
46. I. A. Hekal and E. I. Ibrahiem: Obesity-PSA relationship: A new formula. Prostate Cancer Prostatic Dis, 13(2), 186-90
47. A. J. Armstrong, S. Halabi, R. de Wit, I. F. Tannock and M. Eisenberger: The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis, 12(1), 88-93 (2009)
48. J. K. Parsons, A. V. Sarma, K. McVary and J. T. Wei: Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol, 182(6 Suppl), S27-31 (2009)
49. S. J. Freedland, E. A. Platz, J. C. Presti, Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris: Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J Urol, 175(2), 500-4; discussion 504 (2006)
50. J. C. Presti, Jr., U. Lee, J. D. Brooks and M. K. Terris: Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol, 171(6 Pt 1), 2199-202 (2004)
51. S. J. Freedland, M. K. Terris, E. A. Platz and J. C. Presti, Jr.: Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology, 66(1), 108-13 (2005)
52. P. Motamedinia, R. Korets, B. A. Spencer, M. C. Benson and J. M. McKiernan: Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology, 72(5), 1106-10 (2008)
53. S. A. Siddiqui, B. A. Inman, S. Sengupta, J. M. Slezak, E. J. Bergstralh, B. C. Leibovich, H. Zincke and M. L. Blute: Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer, 107(3), 521-9 (2006)
54. J. G. Van Roermund, K. A. Hinnen, J. J. Battermann, J. A. Witjes, J. L. Bosch, L. A. Kiemeney and M. Van Vulpen: Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. BJU Int, 105(1), 42-8
55. C. E. Paaskesen and M. Borre: Body mass index and prognostic markers at radical prostatectomy. Scand J Urol Nephrol, 42(3), 230-6 (2008)
56. S. J. Freedland, W. J. Aronson, C. J. Kane, J. C. Presti, Jr., C. L. Amling, D. Elashoff and M. K. Terris: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol, 22(3), 446-53 (2004)
57. C. L. Amling, R. H. Riffenburgh, L. Sun, J. W. Moul, R. S. Lance, L. Kusuda, W. J. Sexton, D. W. Soderdahl, T. F. Donahue, J. P. Foley, A. K. Chung and D. G. McLeod: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol, 22(3), 439-45 (2004)
58. W. W. Bassett, M. R. Cooperberg, N. Sadetsky, S. Silva, J. DuChane, D. J. Pasta, J. M. Chan, J. W. Anast, P. R. Carroll and C. J. Kane: Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology, 66(5), 1060-5 (2005)
59. S. S. Strom, X. Wang, C. A. Pettaway, C. J. Logothetis, Y. Yamamura, K. A. Do, R. J. Babaian and P. Troncoso: Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res, 11(19 Pt 1), 6889-94 (2005)
60. C. J. Kane, W. W. Bassett, N. Sadetsky, S. Silva, K. Wallace, D. J. Pasta, M. R. Cooperberg, J. M. Chan and P. R. Carroll: Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. J Urol, 173(3), 732-6 (2005)
61. K. N. Mallah, C. J. DiBlasio, A. C. Rhee, P. T. Scardino and M. W. Kattan: Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer, 103(10), 2030-4 (2005)
62. J. Jayachandran, L. L. Banez, W. J. Aronson, M. K. Terris, J. C. Presti, Jr., C. L. Amling, C. J. Kane and S. J. Freedland: Obesity as a predictor of adverse outcome across black and white race: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer, 115(22), 5263-71 (2009)
63. A. Magheli, S. Rais-Bahrami, B. J. Trock, E. B. Humphreys, A. W. Partin, M. Han and M. L. Gonzalgo: Impact of body mass index on biochemical recurrence rates after radical prostatectomy: An analysis utilizing propensity score matching. Urology, 72(6), 1246-51 (2008)
64. S. J. Freedland, K. A. Grubb, S. K. Yiu, M. E. Nielsen, L. A. Mangold, W. B. Isaacs, J. I. Epstein and A. W. Partin: Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol, 174(5), 1798-801; discussion 1801 (2005)
65. K. W. Kwak, H. M. Lee and H. Y. Choi: Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy. Prostate Cancer Prostatic Dis, 13(1), 28-33
66. E. P. Castle, F. Atug, M. Woods, R. Thomas and R. Davis: Impact of body mass index on outcomes after robot assisted radical prostatectomy. World J Urol, 26(1), 91-5 (2008)
67. M. P. Herman, J. D. Raman, S. Dong, D. Samadi and D. S. Scherr: Increasing body mass index negatively impacts outcomes following robotic radical prostatectomy. Jsls, 11(4), 438-42 (2007)
68. D. Palma, T. Pickles and S. Tyldesley: Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int, 100(2), 315-9 (2007)
69. S. S. Strom, A. M. Kamat, S. K. Gruschkus, Y. Gu, S. Wen, M. R. Cheung, L. L. Pisters, A. K. Lee, C. J. Rosser and D. A. Kuban: Influence of obesity on biochemical and clinical failure after external-Beam radiotherapy for localized prostate cancer. Cancer, 107(3), 631-9 (2006)
70. S. P. Stroup, J. Cullen, B. K. Auge, J. O. L'Esperance and S. K. Kang: Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer, 110(5), 1003-9 (2007)
71. J. A. Efstathiou, M. H. Chen, A. A. Renshaw, M. J. Loffredo and A. V. D'Amico: Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer, 109(8), 1493-8 (2007)
72. G. S. Merrick, W. M. Butler, K. E. Wallner, R. W. Galbreath, Z. Allen, J. H. Lief and E. Adamovich: Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology, 65(1), 95-100 (2005)
73. G. S. Merrick, R. W. Galbreath, W. M. Butler, K. E. Wallner, Z. A. Allen and E. Adamovich: Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol, 30(6), 588-96 (2007)
74. J. R. Wong, Z. Gao, S. Merrick, P. Wilson, M. Uematsu, K. Woo and C. W. Cheng: Potential for higher treatment failure in obese patients: Correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys, 75(1), 49-55 (2009)
75. L. E. Millender, M. Aubin, J. Pouliot, K. Shinohara and M. Roach, 3rd: Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 59(1), 6-10 (2004)
76. S. J. Freedland, M. K. Terris, J. C. Presti, Jr., C. L. Amling, C. J. Kane, B. Trock and W. J. Aronson: Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol, 172(2), 520-4 (2004)
77. C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacobs, A. Chao and M. J. Thun: Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev, 10(4), 345-53 (2001)
78. J. A. Efstathiou, K. Bae, W. U. Shipley, G. E. Hanks, M. V. Pilepich, H. M. Sandler and M. R. Smith: Obesity and mortality in men with locally advanced prostate cancer: Analysis of RTOG 85-31. Cancer, 110(12), 2691-9 (2007)
79. Z. Gong, I. Agalliu, D. W. Lin, J. L. Stanford and A. R. Kristal: Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-Aged men. Cancer, 109(6), 1192-202 (2007)
80. J. Ma, H. Li, E. Giovannucci, L. Mucci, W. Qiu, P. L. Nguyen, J. M. Gaziano, M. Pollak and M. J. Stampfer: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol, 9(11), 1039-47 (2008)
81. C. L. Parr, G. D. Batty, T. H. Lam, F. Barzi, X. Fang, S. C. Ho, S. H. Jee, A. Ansary-Moghaddam, K. Jamrozik, H. Ueshima, M. Woodward and R. R. Huxley: Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants. Lancet Oncol
82. M. Okasha, P. McCarron, J. McEwen and G. D. Smith: Body mass index in young adulthood and cancer mortality: A retrospective cohort study. J Epidemiol Community Health, 56(10), 780-4 (2002)
83. G. Raven, F. H. de Jong, J. M. Kaufman and W. de Ronde: In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab, 91(9), 3324-8 (2006)
84. M. A. Hoffman, W. C. DeWolf and A. Morgentaler: Is low serum free testosterone a marker for high grade prostate cancer? J Urol, 163(3), 824-7 (2000)
85. G. W. Chodak, N. J. Vogelzang, R. J. Caplan, M. Soloway and J. A. Smith: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. Jama, 265(5), 618-21 (1991)
86. G. Schatzl, S. Madersbacher, T. Thurridl, J. Waldmuller, G. Kramer, A. Haitel and M. Marberger: Figh-Grade prostate cancer is associated with low serum testosterone levels. Prostate, 47(1), 52-8 (2001)
87. E. A. Platz, M. F. Leitzmann, N. Rifai, P. W. Kantoff, Y. C. Chen, M. J. Stampfer, W. C. Willett and E. Giovannucci: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostatespecific antigen era. Cancer Epidemiol Biomarkers Prev, 14(5), 1262-9 (2005)
88. G. Severi, H. A. Morris, R. J. MacInnis, D. R. English, W. Tilley, J. L. Hopper, P. Boyle and G. G. Giles: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 15(1), 86-91 (2006)
89. A. W. Roddam, N. E. Allen, P. Appleby and T. J. Key: Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst, 100(3), 170-83 (2008)
90. C. Huggins and C. V. Hodges: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol, 167(2 Pt 2), 948-51; discussion 952 (2002)
91. J. R. Drago: The induction of NB rat prostatic carcinomas. Anticancer Res, 4(4-5), 255-6 (1984)
92. I. Leav, F. B. Merk, P. W. Kwan and S. M. Ho: Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate, 15(1), 23-40 (1989)
93. M. C. Bosland, H. Ford and L. Horton: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis, 16(6), 1311-7 (1995)
94. E. L. Cavalieri, P. Devanesan, M. C. Bosland, A. F. Badawi and E. G. Rogan: Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: Implications for estrogeninduced initiation of prostate cancer. Carcinogenesis, 23(2), 329-33 (2002)
95. E. Cavalieri, K. Frenkel, J. G. Liehr, E. Rogan and D. Roy: Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr(27), 75-93 (2000)
96. N. L. Nock, M. S. Cicek, L. Li, X. Liu, B. A. Rybicki, A. Moreira, S. J. Plummer, G. Casey and J. S. Witte: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis, 27(9), 1842-8 (2006)
97. O. Cussenot, A. R. Azzouzi, N. Nicolaiew, G. Fromont, P. Mangin, L. Cormier, G. Fournier, A. Valeri, S. Larre, F. Thibault, J. P. Giordanella, M. Pouchard, Y. Zheng, F. C. Hamdy, A. Cox and G. Cancel-Tassin: Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens. J Clin Oncol, 25(24), 3596-602 (2007)
98. H. Bonkhoff, T. Fixemer, I. Hunsicker and K. Remberger: Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol, 155(2), 641-7 (1999)
99. I. Y. Kim, D. H. Seong, B. C. Kim, D. K. Lee, A. T. Remaley, F. Leach, R. A. Morton and S. J. Kim: Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res, 62(13), 3649-53 (2002)
100. Y. Kim, B. C. Kim, D. H. Seong, D. K. Lee, J. M. Seo, Y. J. Hong, H. T. Kim, R. A. Morton and S. J. Kim: Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res, 62(18), 5365-9 (2002)
101. B. L. Neubauer, K. L. Best, D. F. Counts, R. L. Goode, D. M. Hoover, C. D. Jones, M. F. Sarosdy, C. J. Shaar, L. R. Tanzer and R. L. Merriman: Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Prostate, 27(4), 220-9 (1995)
102. S. Raghow, M. Z. Hooshdaran, S. Katiyar and M. S. Steiner: Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res, 62(5), 1370-6 (2002)
103. D. Price, B. Stein, P. Sieber, R. Tutrone, J. Bailen, E. Goluboff, D. Burzon, D. Bostwick and M. Steiner: Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-Blind, placebo controlled, phase IIB clinical trial. J Urol, 176(3), 965-70; discussion 970-1 (2006)
104. E. E. Calle and R. Kaaks: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4(8), 579-91 (2004)
105. A. W. Hsing, S. Chua, Jr., Y. T. Gao, E. Gentzschein, L. Chang, J. Deng and F. Z. Stanczyk: Prostate cancer risk and serum levels of insulin and leptin: A population-Based study. J Natl Cancer Inst, 93(10), 783-9 (2001)
106. S. Lehrer, E. J. Diamond, S. Stagger, N. N. Stone and R. G. Stock: Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer, 87(7), 726-8 (2002)
107. J. Hammarsten and B. Hogstedt: Fyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer, 41(18), 2887-95 (2005)
108. M. L. Neuhouser, C. Till, A. Kristal, P. Goodman, A. Hoque, E. A. Platz, A. W. Hsing, D. Albanes, H. L. Parnes and M. Pollak: Finasteride modifies the relation between serum C-peptide and prostate cancer risk: Results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa), 3(3), 279-89
109. S. Bonovas, K. Filioussi and A. Tsantes: Diabetes mellitus and risk of prostate cancer: A meta-Analysis. Diabetologia, 47(6), 1071-8 (2004)
110. E. Jequier: Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci, 967, 379-88 (2002)
111. S. Chang, S. D. Hursting, J. H. Contois, S. S. Strom, Y. Yamamura, R. J. Babaian, P. Troncoso, P. S. Scardino, T. M. Wheeler, C. I. Amos and M. R. Spitz: Leptin and prostate cancer. Prostate, 46(1), 62-7 (2001)
112. P. Stattin, R. Palmqvist, S. Soderberg, C. Biessy, B. Ardnor, G. Hallmans, R. Kaaks and T. Olsson: Plasma leptin and colorectal cancer risk: A prospective study in Northern Sweden. Oncol Rep, 10(6), 2015-21 (2003)
113. S. J. Freedland, L. J. Sokoll, L. A. Mangold, D. J. Bruzek, P. Mohr, S. K. Yiu, J. I. Epstein and A. W. Partin: Serum leptin and pathological findings at the time of radical prostatectomy. J Urol, 173(3), 773-6 (2005)
114. H. Li, M. J. Stampfer, L. Mucci, N. Rifai, W. Qiu, T. Kurth and J. Ma: A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem, 56(1), 34-43
115. S. C. Moore, M. F. Leitzmann, D. Albanes, S. J. Weinstein, K. Snyder, J. Virtamo, J. Ahn, S. T. Mayne, H. Yu, U. Peters and M. J. Gunter: Adipokine genes and prostate cancer risk. Int J Cancer, 124(4), 869-76 (2009)
116. P. Somasundar, K. A. Frankenberry, H. Skinner, G. Vedula, D. W. McFadden, D. Riggs, B. Jackson, R. Vangilder, S. M. Hileman and L. C. Vona-Davis: Prostate cancer cell proliferation is influenced by leptin. J Surg Res, 118(1), 71-82 (2004)
117. P. Somasundar, A. K. Yu, L. Vona-Davis and D. W. McFadden: Differential effects of leptin on cancer in vitro. J Surg Res, 113(1), 50-5 (2003)
118. M. Onuma, J. D. Bub, T. L. Rummel and Y. Iwamoto: Prostate cancer cell-Adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem, 278(43), 42660-7 (2003)
119. T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M. L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel and T. Kadowaki: The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 7(8), 941-6 (2001)
120. J. D. Bub, T. Miyazaki and Y. Iwamoto: Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun, 340(4), 1158-66 (2006)
121. S. J. Freedland, L. J. Sokoll, E. A. Platz, L. A. Mangold, D. J. Bruzek, P. Mohr, S. K. Yiu and A. W. Partin: Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol, 174(4 Pt 1), 1266-70 (2005)
122. D. J. Sher, W. K. Oh, S. Jacobus, M. M. Regan, G. S. Lee and C. Mantzoros: Relationship between serum adiponectin and prostate cancer grade. Prostate, 68(14), 1592-8 (2008)